--- title: Understanding the breast cancer patient journey in 2025 description: See how HealthVerity taXonomy Pathways links claims, EHR, labs, and imaging to reveal a comprehensive breast cancer patient journey. image: https://blog.healthverity.com/hubfs/understanding-the-breast-cancer-patient-journey-in-2025-featured.png --- Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/) - [Contact](https://healthverity.com/contact/) - [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/) [![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/) - How We Help - Featured Content - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Life Sciences](https://healthverity.com/life-sciences/) - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - Data Ecosystem - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/) - [Media Measurement](https://healthverity.com/media-measurement/) - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/) - Technology Products - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - [HealthVerity FLOW](https://healthverity.com/flow/portal/) - [Governance Manager](https://healthverity.com/governance-manager/) - [Smart Contracts](https://healthverity.com/smart-contracts-manager/) - Symphony - Symphony Health Platform - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/) - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - Symphony Solutions - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/) - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/) - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/) - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/) - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/) - Symphony Products - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf) - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf) - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf) - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf) - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf) - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf) - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf) - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf) - Symphony Technology - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf) - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/) - Who We Serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) - Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) - [Zombie Data Explained](https://healthverity.com/get-verified/) - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) [Trends & Insights](https://blog.healthverity.com/tag/trends-insights), [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices), [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims) # Understanding the breast cancer patient journey in 2025 [By \- HealthVerity,](https://blog.healthverity.com/author/healthverity) October 29, 2025 ![](https://blog.healthverity.com/hubfs/understanding-the-breast-cancer-patient-journey-in-2025-featured.png) October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring attention to the disease, the latest data show that breast cancer remains a pressing public health issue. In 2025, about **1 in 8** women in the U.S. will develop breast cancer during their lifetime.1 An estimated 316,950 women and 2,800 men will be diagnosed with invasive breast cancer this year, with another 59,080 diagnosed with ductal carcinoma in situ. Mortality rates have declined by roughly 44% since 1989. thanks to earlier detection and improved therapies, yet disparities persist. Black women, for example, have a breast‑cancer incidence rate slightly lower than white women but a 38% higher mortality rate.1 Thanks to earlier detection and improved treatments, more than 4 million survivors now live in the United States, yet breast cancer remains the second-leading cause of cancer death among women.1 That mix of progress and persistence demonstrates why it’s critical to understand each patient’s full experience, starting from screening and diagnosis to treatment and survivorship. **The details of a patient’s care pathway reveal where interventions succeed and where disparities remain, particularly among populations more likely to experience aggressive disease or delayed diagnosis.** Through [taXonomy Pathways](https://healthverity.com/pathways/), we enable researchers and life-science organizations to build a comprehensive picture of the patient journey. By unifying real-world data (RWD) across closed claims, electronic health records (EHR), lab results, biomarkers, imaging and even physician notes, HealthVerity helps uncover the clinical context that traditional data aggregators and closed claims alone often miss. These synchronized insights enable scientists and public-health experts to study *how* and *why* breast cancer evolves, how treatments perform, and where gaps in access or equity persist, all with the precision and outstanding privacy safeguards that define the HealthVerity data ecosystem. [![Close the evidence gap with taXonomy Pathways](https://no-cache.hubspot.com/cta/default/5412465/interactive-196135223637.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIJhOEtzuTyXsXd0QJQpVIQh7AZaOBPqLPTaWBV06tz6osDJ3JeITg37gcIsqo0enPb64Oq2MvpdvM%2BgdHqwEuZQUryYzOXEZ7hmLam7wOb5M3UhGy0zRCo2APuxQ22xG9cEQ84rrEKr0QB7fjgeMOhrsA21m5mh6kVmf1XSuZj3MoY%2F%2BwFMWx8%2FRLqJZpWf2IY3tDmZ3gV&webInteractiveContentId=196135223637&portalId=5412465) ## Beyond statistics: why the patient journey matters National campaigns often focus on raising awareness, but seeing patients only as numbers hides the complexity of their experiences. Survivorship is not only about avoiding death; it includes quality of life, mental health and financial impact. To develop treatments that **improve outcomes** and **reduce inequities**, researchers need a detailed view of the patient journey from preventive care through diagnosis, treatment and long‑term follow‑up. Real‑world data (RWD) provide that comprehensive view. By combining information from medical claims, electronic health records (EHR), laboratory results, pharmacy claims and even imaging and physician notes, analysts can observe how patients move through the healthcare system. RWD can help: - **Identify eligible trial participants.** Linked claims and EHR data reveal patients with specific tumor subtypes, genetic mutations or comorbid conditions. - **Monitor patients during studies.** Continuously updating claims and lab records offer insights into healthcare utilization and adherence outside of the trial setting. - **Create control arms.** RWD enables concurrent or external control arms for clinical trials, reducing the need for placebo groups. - **Conduct long‑term follow‑up.** Longitudinal data help researchers evaluate real‑world safety and effectiveness years after a product enters the market. ## Patient story: following a breast cancer patient in real-time To illustrate how comprehensive data reveal the patient journey, consider **Gina**, a 34‑year‑old Black woman (represented by a de‑identified HealthVerity ID) who diligently attends her preventive appointments. Her story is hypothetical but reflects common clinical scenarios and shows how linking claims, EHR, labs and other data sources helps clinicians and researchers understand breast‑cancer pathways and outcomes. ![taxonomy-pathways-diagram-alt](https://blog.healthverity.com/hs-fs/hubfs/taxonomy-pathways-diagram-alt.png?width=637&height=282&name=taxonomy-pathways-diagram-alt.png) ### Routine preventive care During her **annual wellness visit**, **claims and EHR** data show that Gina’s vital signs and lab results are normal. She has a diagnosis of obesity but no family history of breast cancer, and her physical breast exam is unremarkable. Six months later, at her **annual gynecologist visit**, **claims** and **lab records** indicate that she had a Pap smear and human papillomavirus (HPV) test. During the visit **physician notes** indicate **she reports a lump** and swelling in her right breast. The gynecologist documents the mass in the EHR and refers her for a mammogram. ### Screening and diagnosis Two weeks later the **lab results** from her gynecologic visit show a positive HPV test but a normal Pap smear. Gina visits an imaging center for a screening **mammogram**. The radiologist notes an abnormality and orders a breast MRI. The **EHR** captures these tests along with her reported symptoms. The **MRI** reveals a small mass, prompting a referral to an oncologist. At the **oncology consult**, **claims data** show orders for BRCA testing, hormone‑receptor assays (estrogen receptor \[ER\], progesterone receptor \[PR\] and HER2) and an ultrasound‑guided biopsy. Because Gina is young and Black, the oncologist wants to rule out hereditary risk factors. The **genetic test** results indicate a BRCA1 mutation, one of the inherited gene alterations responsible for 5–10% of breast cancers.1 A few days later, the pathology report confirms triple‑negative breast cancer (TNBC). TNBC lacks ER, PR and HER2 receptors and therefore does not respond to hormone therapy or HER2‑targeted drugs; it accounts for roughly 10% of breast cancers overall but 20% of cases in Black women.1 ### Treatment decisions Gina and her oncologist discuss treatment options. Because TNBC tends to grow quickly and has a higher risk of recurrence, they decide on a mastectomy followed by radiation therapy. **Claims data** indicate that during a pre‑surgery follow‑up visit Gina reports symptoms of depression and anxiety. Her **EHR documents and physician notes** reflect this and a referral to a mental‑health specialist and initiation of an antidepressant. **Pharmacy claims** indicate that Gina picked up the prescription. ### Surgery and post‑operative care The **EHR**, **claims** and **lab data** show that Gina undergoes a **mastectomy** with clear margins. Post‑operative pathology confirms that the tumor was small and lymph nodes are negative.  ### Radiation and follow‑up After her incision heals, Gina begins **radiation therapy** five days a week for six weeks. **Claims** and **EHR** records document each session. Over the next year, regular follow‑up visits include blood tests and imaging to monitor for recurrences that are captured in **labs**. Gina’s RWD shows no new symptoms or abnormal results. She enters **remission** and continues to receive periodic surveillance. ## How taXonomy Pathways enriches the patient journey [**taXonomy Pathways**](https://healthverity.com/pathways/) initiative expands the scope of RWD by connecting disparate datasets—closed medical and pharmacy claims, EHRs, laboratory results, imaging, repeated measures such as vital signs and physician notes—under a single, privacy‑preserving framework. Traditional claims data provide a broad view of diagnoses and healthcare utilization, but they often lack clinical detail. taXonomy Pathways fills that gap by: - **Linking claims with rich clinical data.** It captures biomarker testing, genetic results, therapy selections and disease progression events from EHRs and clinician notes. In oncology, for example, researchers can observe which patients undergo BRCA testing or receive targeted therapies, not just that they were billed for an infusion. - **Tracking repeated measures over time.** Longitudinal records of weight, body‑mass index, blood pressure and laboratory values allow analysts to assess treatment response and comorbid conditions in obesity and metabolic disease. - **Integrating imaging and diagnostic data.** Mammograms, MRIs and other images provide context about tumor size and spread, while pathology and radiology reports add granularity. - **Maintaining patient identity resolution.** The HealthVerity privacy‑preserving identity framework allows data from multiple sources to be synchronized for the same individual without revealing personal identifiers, ensuring HIPAA compliance. By going **beyond claims**, [taXonomy Pathways](https://healthverity.com/pathways/) delivers a **comprehensive patient journey**, enabling researchers and life‑science companies to generate robust real‑world evidence. This holistic view supports health economics and outcomes research (HEOR), pharmacovigilance, clinical trial feasibility studies, and analyses of health disparities. It also empowers clinicians and advocates to design interventions that improve outcomes and equity. [![Close the evidence gap with taXonomy Pathways](https://no-cache.hubspot.com/cta/default/5412465/interactive-196135223637.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIJhOEtzuTyXsXd0QJQpVIQh7AZaOBPqLPTaWBV06tz6osDJ3JeITg37gcIsqo0enPb64Oq2MvpdvM%2BgdHqwEuZQUryYzOXEZ7hmLam7wOb5M3UhGy0zRCo2APuxQ22xG9cEQ84rrEKr0QB7fjgeMOhrsA21m5mh6kVmf1XSuZj3MoY%2F%2BwFMWx8%2FRLqJZpWf2IY3tDmZ3gV&webInteractiveContentId=196135223637&portalId=5412465) ## References 1. American Cancer Society. *Breast Cancer Facts & Figures 2024-2025*. Atlanta, GA: American Cancer Society; 2024. Accessed October 27, 2025.[https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html](https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html) ###### Category - [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices) - [Trends & Insights](https://blog.healthverity.com/tag/trends-insights) - [HEOR](https://blog.healthverity.com/tag/heor) - [Marketplace (RWD)](https://blog.healthverity.com/tag/marketplace-rwd) - [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership) - [Industry Updates](https://blog.healthverity.com/tag/industry-updates) - [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims) - [Case Studies](https://blog.healthverity.com/tag/case-studies) - [Commercial Pharma](https://blog.healthverity.com/tag/commercial-pharma) - [AI](https://blog.healthverity.com/tag/ai) - [Government](https://blog.healthverity.com/tag/government) - [eXOs](https://blog.healthverity.com/tag/exos) - [Audiences](https://blog.healthverity.com/tag/audiences) - [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways) - [Clinical Notes](https://blog.healthverity.com/tag/clinical-notes) - [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) ###### Popular Post - [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) - [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) - [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) - [An integrated approach for deeper insight with both open and closed claims data](https://blog.healthverity.com/an-integrated-approach-for-deeper-insight-with-both-open-and-closed-claims-data) - [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) ###### Subscribe ### Similar Blogs [![More than data: Synchronizing the breast cancer patient story](https://blog.healthverity.com/hs-fs/hubfs/more-than-data-synchronizing-the-breast-cancer-patient-story.jpg?width=352&name=more-than-data-synchronizing-the-breast-cancer-patient-story.jpg)](https://blog.healthverity.com/breast-cancer-patient-story) #### [More than data: Synchronizing the breast cancer patient story](https://blog.healthverity.com/breast-cancer-patient-story) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 25 October 2023 One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime, that’s one... [READ MORE](https://blog.healthverity.com/understanding-the-breast-cancer-patient-journey-in-2025) [![Real-world data for heart failure: Closing evidence gaps across the patient journey](https://blog.healthverity.com/hs-fs/hubfs/real-world-data-for-heart-failure-featured.png?width=352&name=real-world-data-for-heart-failure-featured.png)](https://blog.healthverity.com/real-world-data-for-heart-failure-closing-evidence-gaps-across-the-patient-journey) #### [Real-world data for heart failure: Closing evidence gaps across the patient journey](https://blog.healthverity.com/real-world-data-for-heart-failure-closing-evidence-gaps-across-the-patient-journey) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 16 October 2025 The evolution of heart failure treatment and research Heart failure remains one of the most... [READ MORE](https://blog.healthverity.com/understanding-the-breast-cancer-patient-journey-in-2025) [![How GLP-1 direct-to-consumer programs are distorting utilization trends](https://blog.healthverity.com/hs-fs/hubfs/glp-1-dtc-blog.png?width=352&name=glp-1-dtc-blog.png)](https://blog.healthverity.com/how-glp-1-direct-to-consumer-programs-are-distorting-utilization-trends) #### [How GLP-1 direct-to-consumer programs are distorting utilization trends](https://blog.healthverity.com/how-glp-1-direct-to-consumer-programs-are-distorting-utilization-trends) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 14 January 2026 Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to... [READ MORE](https://blog.healthverity.com/understanding-the-breast-cancer-patient-journey-in-2025) #### Who we serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) #### How we help - [HealthVerity Marketplace](https://healthverity.com/marketplace/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/) - [HealthVerity FLOW](https://healthverity.com/flow/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) #### Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) #### Our company - [About Us](https://healthverity.com/about-us/) - [Leadership](https://healthverity.com/about-us/#leadership) - [Board of Directors](https://healthverity.com/about-us/#board) - [Careers](https://healthverity.com/careers/) - [Contact](https://healthverity.com/contact/) ©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/)